FI3934637T3 - (N)-asetyyli-L-leusiini käytettäväksi traumaattisen aivovaurion hoitamisessa - Google Patents

(N)-asetyyli-L-leusiini käytettäväksi traumaattisen aivovaurion hoitamisessa Download PDF

Info

Publication number
FI3934637T3
FI3934637T3 FIEP20712029.6T FI20712029T FI3934637T3 FI 3934637 T3 FI3934637 T3 FI 3934637T3 FI 20712029 T FI20712029 T FI 20712029T FI 3934637 T3 FI3934637 T3 FI 3934637T3
Authority
FI
Finland
Prior art keywords
leucine
acetyl
pharmaceutically acceptable
acceptable salt
subject
Prior art date
Application number
FIEP20712029.6T
Other languages
English (en)
Finnish (fi)
Inventor
Mallory Factor
Taylor Fields
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Application granted granted Critical
Publication of FI3934637T3 publication Critical patent/FI3934637T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIEP20712029.6T 2019-03-02 2020-03-02 (N)-asetyyli-L-leusiini käytettäväksi traumaattisen aivovaurion hoitamisessa FI3934637T3 (fi)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962812987P 2019-03-02 2019-03-02
US201962842296P 2019-05-02 2019-05-02
US201962888894P 2019-08-19 2019-08-19
US201962895144P 2019-09-03 2019-09-03
PCT/IB2020/051767 WO2020178721A1 (en) 2019-03-02 2020-03-02 Leucine, acetyl leucine, and related analogs for treating disease

Publications (1)

Publication Number Publication Date
FI3934637T3 true FI3934637T3 (fi) 2024-09-02

Family

ID=69845470

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20712029.6T FI3934637T3 (fi) 2019-03-02 2020-03-02 (N)-asetyyli-L-leusiini käytettäväksi traumaattisen aivovaurion hoitamisessa

Country Status (25)

Country Link
US (1) US20220142959A1 (cg-RX-API-DMAC10.html)
EP (2) EP4464378A3 (cg-RX-API-DMAC10.html)
JP (2) JP7555346B2 (cg-RX-API-DMAC10.html)
KR (2) KR102941068B1 (cg-RX-API-DMAC10.html)
CN (2) CN119097618A (cg-RX-API-DMAC10.html)
AU (2) AU2020231189B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021017203A2 (cg-RX-API-DMAC10.html)
CA (1) CA3131948A1 (cg-RX-API-DMAC10.html)
DK (1) DK3934637T3 (cg-RX-API-DMAC10.html)
ES (1) ES2990183T3 (cg-RX-API-DMAC10.html)
FI (1) FI3934637T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20241150T1 (cg-RX-API-DMAC10.html)
HU (1) HUE068527T2 (cg-RX-API-DMAC10.html)
IL (2) IL321899A (cg-RX-API-DMAC10.html)
LT (1) LT3934637T (cg-RX-API-DMAC10.html)
MA (1) MA55199B1 (cg-RX-API-DMAC10.html)
MD (1) MD3934637T2 (cg-RX-API-DMAC10.html)
MX (2) MX2021010568A (cg-RX-API-DMAC10.html)
PL (1) PL3934637T3 (cg-RX-API-DMAC10.html)
PT (1) PT3934637T (cg-RX-API-DMAC10.html)
RS (1) RS65849B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202109512SA (cg-RX-API-DMAC10.html)
SI (1) SI3934637T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400334T1 (cg-RX-API-DMAC10.html)
WO (1) WO2020178721A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
CN120157593A (zh) 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
WO2022125304A1 (en) * 2020-12-10 2022-06-16 Texas Tech University System Bcaa-lowering compounds for prevention and/or treatment of alzheimer's disease and related disorders
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
WO2024243004A2 (en) * 2023-05-19 2024-11-28 The Children's Hospital Of Philadelphia Compositions and methods for treating traumatic brain injury
WO2025166100A1 (en) * 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders
WO2025175092A1 (en) * 2024-02-14 2025-08-21 Intrabio Inc. Acetyl leucine for treating syngap1-related disorders
TW202604470A (zh) * 2024-06-20 2026-02-01 美商音特拉拜歐公司 乙醯白胺酸用於治療神經發育障礙

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
US20140080885A1 (en) * 2012-09-13 2014-03-20 University Of South Florida (A Florida Non-Profit Corporation) Methods of treating traumatic brain injury
PT3445351T (pt) * 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
PT3482754T (pt) 2016-08-11 2021-02-03 Intrabio Ltd Composições farmacêuticas e utilizações contra os distúrbios de armazenamento lisossómico
TN2019000033A1 (fr) * 2016-08-11 2020-07-15 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
US20190046486A1 (en) * 2017-08-14 2019-02-14 Axcella Health Inc. Compositions and methods for the treatment of neuronal injury

Also Published As

Publication number Publication date
CA3131948A1 (en) 2020-09-10
EP3934637A1 (en) 2022-01-12
RS65849B1 (sr) 2024-09-30
SMT202400334T1 (it) 2024-09-16
HRP20241150T1 (hr) 2024-11-22
AU2020231189A1 (en) 2021-09-30
MA55199A (fr) 2022-01-12
AU2025204995A1 (en) 2025-07-17
EP4464378A3 (en) 2025-04-09
EP3934637B1 (en) 2024-07-31
CN114040757B (zh) 2024-09-20
KR102941068B1 (ko) 2026-03-18
MA55199B1 (fr) 2024-08-30
MD3934637T2 (ro) 2024-12-31
JP2024170602A (ja) 2024-12-10
PT3934637T (pt) 2024-08-30
WO2020178721A1 (en) 2020-09-10
IL285870B1 (en) 2025-08-01
BR112021017203A2 (pt) 2021-12-14
CN119097618A (zh) 2024-12-10
CN114040757A (zh) 2022-02-11
PL3934637T3 (pl) 2024-10-14
JP7555346B2 (ja) 2024-09-24
IL321899A (en) 2025-09-01
US20220142959A1 (en) 2022-05-12
EP4464378A2 (en) 2024-11-20
IL285870A (en) 2021-10-31
MX2024015063A (es) 2025-01-09
LT3934637T (lt) 2024-08-26
JP2022522819A (ja) 2022-04-20
MX2021010568A (es) 2021-11-12
ES2990183T3 (es) 2024-11-29
AU2020231189B2 (en) 2025-07-24
KR20250171484A (ko) 2025-12-08
HUE068527T2 (hu) 2025-01-28
IL285870B2 (en) 2025-12-01
DK3934637T3 (da) 2024-09-02
SG11202109512SA (en) 2021-09-29
KR20210135272A (ko) 2021-11-12
SI3934637T1 (sl) 2024-10-30

Similar Documents

Publication Publication Date Title
HRP20241150T1 (hr) (n-)acetil-l-leucin za uporabu u liječenju traumatske ozljede mozga
JP2022522819A5 (cg-RX-API-DMAC10.html)
FI4084791T3 (fi) Spesifisiä tryptamiinejä käytettäviksi mielialahäiriöiden hoidossa
EP4424328A3 (en) Treatment of hidradenitis suppurativa using jak inhibitors
RU2017121191A (ru) Методика размножения гамма-дельта Т-клеток
RU2016141570A (ru) Комбинации ингибитора fgfr и ингибитора igf1r
Kalita et al. State-of-the-art review-A review on snake venom-derived antithrombotics: Potential therapeutics for COVID-19-associated thrombosis?
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
ATE290525T1 (de) Acylaminoalkyl-substituierte benzolsulfonamidderivate
ES440982A1 (es) Instalacion para el tratamiento de superficies de piezas a trabajar, especialmente para el lavado de piezas metalicas.
WO2023114557A3 (en) METHODS OF TREATING SUBSTANCE USE DISORDERS USING 5-MeO-DMT
WO2025137652A3 (en) Compositions comprising radiprodil and the use of radiprodil in the treatment of epileptic or neurobehavioral disorders
EP3048886B1 (en) 3, 4-bis-benzylsulfonylbutanenitrile and its pharmaceutical use
CN107485791A (zh) 一种利用积分波微磁场的偏头痛治疗仪
CERA Emetine toxicity with electrocardiographic abnormalities
Rabinovich et al. Functional cardiovascular assessment in dentists performing local anesthesia in out-patient settings
MX2023006863A (es) Uso de la cladribina en el tratamiento de enfermedades neurológicas autoinmunes.
RU2016147455A (ru) Способ лечения кожных проявлений склеродермии
Serdyuk et al. Development of the combined medication composition for symptomatic pseudorheumatism treatment
RU2003135781A (ru) Способ лечения ревматоидного артрита
GOETTE et al. Liquid nitrogen in the treatment of acne vulgaris: a comparative study
Carvalho et al. Modulation of adult neurogenesis by the nitric oxide system
Yang OBSERVATION OF THE IMMEDIATE EFFECT OF ELECTROACUPUNCTURE AT “LINGTAI” AND “SHENDAO” POINTS ON ST-T SEGMENT OF EKG IN PATIENTS WITH CORONARY HEART DISEASE
RU161528U1 (ru) Способ комплексного лечения больных бляшечным псориазом
RU2007106415A (ru) Способ лечения тяжелой формы вульгарных угрей